Literature DB >> 16761474

Early oral feeding in acute pancreatitis: an alternative approach to tube feeding. Preliminary report.

G Pupelis1, K Snippe, H Plaudis, M Rudakovska.   

Abstract

INTRODUCTION: Jejunal feeding is accepted in the treatment of severe acute pancreatitis (AP). Early oral feeding (EOF) is deemed to be detrimental in the early phase of AP. The aim of this study was to assess the safety and effectiveness of EOF in the treatment of AP.
MATERIALS AND METHODS: 29 AP patients were prospectively enrolled within 1.96 days from the onset of disease. APACHE II score, SIRS, MODS, serum CRP and lipase were evaluated. All patients received EOF when gastro-enteric transit was not severely impaired. ICU, hospital stay and main outcomes were assessed.
RESULTS: APACHE II score was > or = 8 in 10 patients at the admission ranging 0-13 points for the whole group. Alcohol (62%) and gallstones (38%) were the main etiologic factors. SIRS and MODS were diagnosed in 65% and pleural effusion in 24% of patients. EOF was started on average 3.27 days after admission providing 571 ml (280.0-1115.0 ml) of enteral formula daily for 10.38 days. Median lipase activity was 690 U/l (90-10175 U/l) and CRP concentration reached 91.25 mg/dL (3.5-210 mg/dL) before EOF. Progressive decrease of lipase activity and CRP concentration was observed during the EOF course, reaching median CRP 18.6 mg/L (4.6-96.7mg/L) by discharge. Two patients underwent surgical intervention. Minor side effects of EOF were successfully managed in 4 patients. No mortality was observed.
CONCLUSION: EOF could be a safe and effective alternative of nutritional support in AP patients when gastro-enteric transit is not severely impaired. For better EOF assessment further clinical trials are required.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16761474     DOI: 10.1080/00015458.2006.11679867

Source DB:  PubMed          Journal:  Acta Chir Belg        ISSN: 0001-5458            Impact factor:   1.090


  7 in total

1.  Three initial diets for management of mild acute pancreatitis: a meta-analysis.

Authors:  Wen-Bo Meng; Xun Li; Yu-Min Li; Wen-Ce Zhou; Xiao-Liang Zhu
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Conservative approach in the management of severe acute pancreatitis: eight-year experience in a single institution.

Authors:  G Pupelis; K Zeiza; H Plaudis; A Suhova
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

Review 3.  Evidence-based use of enteral nutrition in acute pancreatitis.

Authors:  Attila Oláh; László Romics
Journal:  Langenbecks Arch Surg       Date:  2010-03-23       Impact factor: 3.445

Review 4.  Enteral nutrition in acute pancreatitis: a review of the current evidence.

Authors:  Attila Oláh; Laszlo Romics
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 5.  Early enteral nutrition in acute pancreatitis--benefits and limitations.

Authors:  Attila Oláh; László Romics
Journal:  Langenbecks Arch Surg       Date:  2008-02-12       Impact factor: 3.445

6.  High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial.

Authors:  Katalin Márta; Anikó N Szabó; Dániel Pécsi; Péter Varjú; Judit Bajor; Szilárd Gódi; Patrícia Sarlós; Alexandra Mikó; Kata Szemes; Mária Papp; Tamás Tornai; Áron Vincze; Zsolt Márton; Patrícia A Vincze; Erzsébet Lankó; Andrea Szentesi; Tímea Molnár; Roland Hágendorn; Nándor Faluhelyi; István Battyáni; Dezső Kelemen; Róbert Papp; Attila Miseta; Zsófia Verzár; Markus M Lerch; John P Neoptolemos; Miklós Sahin-Tóth; Ole H Petersen; Péter Hegyi
Journal:  BMJ Open       Date:  2017-09-14       Impact factor: 2.692

Review 7.  A meta-analysis of early oral refeeding and quickly increased diet for patients with mild acute pancreatitis.

Authors:  Jiran Zhang; Sha Zhu; Dingyu Tan; Aiwen Ma; Yan Yang; Jiyang Xu
Journal:  Saudi J Gastroenterol       Date:  2019 Jan-Feb       Impact factor: 2.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.